AusBiotech links with Japanese industry body on regenerative meds

19 October 2017

AusBiotech signed a memorandum of understanding (MoU) with Japan’s peak regenerative medicine body, Forum for Innovative Regenerative Medicine (FIRM) last week) under the MoU between Australian Trade Commission (Austrade) and FIRM, in relation to the collaboration in advancing regenerative medicine and cell and gene therapies within Australia, Japan and worldwide.

FIRM is a Japanese general incorporated association with a mission to accelerate research and commercialization of regenerative medicine in Japan. FIRM was formed in 2011 and has more than 220 members of Japanese companies from various fields with diverse expertise in such as pharmaceutical, biotechnology, manufacturing, transportation, insurance and related supporting areas for regenerative medicine.

AusBiotech and FIRM will collaborate in advancing their individual and common missions by sharing information, encompassing technology, policy, laws, etc, and assist each other in co-sponsoring meetings or through other cooperation based on common concerns.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK